CTOs on the Move

Medytox Solutions, Incorporated

www.medytoxsolutionsinc.com

 
Medytox Solutions, Inc. develops and delivers cutting-edge testing and reporting technology and systems, providing an affordable and superior service to medical providers. In turn, our medical provider clients are able to provide better and more cost-effective patient care. Medytox offers its clients a complete solution, with faster turnaround times and more reliable and accurate results, in a manner that is safe, secure and HIPAA-compliant in all respects. We conduct our testing on the most accurate and advanced equipment available, using proven methodologies to provide superior results, while supporting our clients with personnel, equipment and turn-key services dedicated to providing them with the ...
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Nanogen

Nanogen, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Atomic Energy Ind Labs

Atomic Energy Ind Labs is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Yocom Mc Coll Testing Labs

Yocom Mc Coll Testing Labs is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Agendia USA

Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing patients with early stage breast cancer and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient. MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings. Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of patients with breast cancer and their physicians every step of the way, from initial diagnosis to cancer-free.

Access Diagnostics

Access Diagnostics is a Detroit, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.